Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment.
Standard
Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment. / Deshaies, Isabelle; Cherenfant, Jovenel; Gusani, Niraj J; Jiang, Yixing; Harvey, Harold A; Kimchi, Eric T; Kaifi, Jussuf; Staveley-O'Carroll, Kevin F.
In: THER CLIN RISK MANAG, Vol. 6, 2010, p. 453-458.Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Gastrointestinal stromal tumor (GIST) recurrence following surgery: review of the clinical utility of imatinib treatment.
AU - Deshaies, Isabelle
AU - Cherenfant, Jovenel
AU - Gusani, Niraj J
AU - Jiang, Yixing
AU - Harvey, Harold A
AU - Kimchi, Eric T
AU - Kaifi, Jussuf
AU - Staveley-O'Carroll, Kevin F
PY - 2010
Y1 - 2010
N2 - Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery with complete removal of the tumor is the primary treatment for resectable GIST and the only chance of cure. However, recurrence after surgery is common. The 2 main prognostic factors are the mitotic activity and the size of the tumor. Tumor rupture is also a risk factor for postoperative recurrence, and extra care should be taken while manipulating this soft and friable tumor. Imatinib mesylate (IM, Gleevec(®), Novartis, Basel, Switzerland) is a tyrosine kinase inhibitor and was first studied in the palliative setting for metastatic GIST patients in the year 2000. It is now the cornerstone of metastatic GIST treatment. IM also plays an important role as an adjuvant treatment for resectable GIST and has been shown to increase the recurrence-free survival in phase III studies. However, some points remain to be clarified. Notably, the ideal duration of adjuvant IM after surgery is still unclear. It is also difficult to determine the exact place of surgery in metastatic or recurrent GIST patients in the IM era. A multidisciplinary approach is, therefore, mandatory to offer GIST patients the best treatment available.
AB - Gastrointestinal stromal tumor (GIST) is the most common mesenchymal tumor of the gastrointestinal tract. Surgery with complete removal of the tumor is the primary treatment for resectable GIST and the only chance of cure. However, recurrence after surgery is common. The 2 main prognostic factors are the mitotic activity and the size of the tumor. Tumor rupture is also a risk factor for postoperative recurrence, and extra care should be taken while manipulating this soft and friable tumor. Imatinib mesylate (IM, Gleevec(®), Novartis, Basel, Switzerland) is a tyrosine kinase inhibitor and was first studied in the palliative setting for metastatic GIST patients in the year 2000. It is now the cornerstone of metastatic GIST treatment. IM also plays an important role as an adjuvant treatment for resectable GIST and has been shown to increase the recurrence-free survival in phase III studies. However, some points remain to be clarified. Notably, the ideal duration of adjuvant IM after surgery is still unclear. It is also difficult to determine the exact place of surgery in metastatic or recurrent GIST patients in the IM era. A multidisciplinary approach is, therefore, mandatory to offer GIST patients the best treatment available.
M3 - SCORING: Journal article
VL - 6
SP - 453
EP - 458
JO - THER CLIN RISK MANAG
JF - THER CLIN RISK MANAG
SN - 1178-203X
ER -
